Literature DB >> 35355115

Native T1 mapping for the diagnosis of cardiac amyloidosis in patients with left ventricular hypertrophy.

Daniel Lavall1, Nicola H Vosshage2, Romy Geßner2, Stephan Stöbe2, Sebastian Ebel3, Timm Denecke3, Andreas Hagendorff2, Ulrich Laufs2.   

Abstract

BACKGROUND: Cardiac magnetic resonance (CMR) with parametric mapping can improve the characterization of myocardial tissue. We studied the diagnostic value of native T1 mapping to detect cardiac amyloidosis in patients with left ventricular (LV) hypertrophy.
METHODS: One hundred twenty-five patients with increased LV wall thickness (≥ 12 mm end-diastole) who received clinical CMR in a 3 T scanner between 2017 and 2020 were included. 31 subjects without structural heart disease served as controls. Native T1 was measured as global mean value from 3 LV short axis slices. The study was registered at German clinical trial registry (DRKS00022048).
RESULTS: Mean age of the patients was 66 ± 14 years, 83% were males. CA was present in 24 patients, 21 patients had hypertrophic cardiomyopathy (HCM), 80 patients suffered from hypertensive heart disease (HHD). Native T1 times were higher in patients with CA (1409 ± 59 ms, p < 0.0001) compared to healthy controls (1225 ± 21 ms), HCM (1266 ± 44 ms) and HHD (1257 ± 41 ms). HCM and HHD patients did not differ in their native T1 times but were increased compared to control (p < 0.01). ROC analysis of native T1 demonstrated an area under the curve for the detection of CA vs. HCM and HHD of 0.9938 (p < 0.0001), which was higher than that of extracellular volume (0.9876) or quantitative late gadolinium enhancement (0.9406; both p < 0.0001). The optimal cut-off value of native T1 to diagnose CA was 1341 ms (sensitivity 100%, specificity 97%).
CONCLUSION: Non-contrast CMR imaging with native T1 mapping provides high diagnostic accuracy to diagnose cardiac amyloidosis in patients with left ventricular hypertrophy.
© 2022. The Author(s).

Entities:  

Keywords:  Cardiac amyloidosis; Cardiac magnetic resonance; Left ventricular hypertrophy; Native T1 mapping

Year:  2022        PMID: 35355115     DOI: 10.1007/s00392-022-02005-2

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  23 in total

Review 1.  Myocardial Amyloidosis: The Exemplar Interstitial Disease.

Authors:  Marianna Fontana; Andrej Ćorović; Paul Scully; James C Moon
Journal:  JACC Cardiovasc Imaging       Date:  2019-08-14

Review 2.  Impact of Late Gadolinium Enhancement on mortality, sudden death and major adverse cardiovascular events in ischemic and nonischemic cardiomyopathy: A systematic review and meta-analysis.

Authors:  Anand N Ganesan; James Gunton; Gaetano Nucifora; Andrew D McGavigan; Joseph B Selvanayagam
Journal:  Int J Cardiol       Date:  2018-01-28       Impact factor: 4.164

Review 3.  Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.

Authors:  Frederick L Ruberg; Martha Grogan; Mazen Hanna; Jeffery W Kelly; Mathew S Maurer
Journal:  J Am Coll Cardiol       Date:  2019-06-11       Impact factor: 24.094

4.  Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis.

Authors:  Andrea Baggiano; Michele Boldrini; Ana Martinez-Naharro; Tushar Kotecha; Aviva Petrie; Tamer Rezk; Maurizio Gritti; Cristina Quarta; Daniel S Knight; Ashutosh D Wechalekar; Helen J Lachmann; Stefano Perlini; Gianluca Pontone; James C Moon; Peter Kellman; Julian D Gillmore; Philip N Hawkins; Marianna Fontana
Journal:  JACC Cardiovasc Imaging       Date:  2019-06-12

Review 5.  Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies.

Authors:  Heiko Mahrholdt; Anja Wagner; Robert M Judd; Udo Sechtem; Raymond J Kim
Journal:  Eur Heart J       Date:  2005-04-14       Impact factor: 29.983

6.  Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling.

Authors:  Andre Rudolph; Hassan Abdel-Aty; Steffen Bohl; Philipp Boyé; Anja Zagrosek; Rainer Dietz; Jeanette Schulz-Menger
Journal:  J Am Coll Cardiol       Date:  2009-01-20       Impact factor: 24.094

7.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

Authors:  Perry M Elliott; Aris Anastasakis; Michael A Borger; Martin Borggrefe; Franco Cecchi; Philippe Charron; Albert Alain Hagege; Antoine Lafont; Giuseppe Limongelli; Heiko Mahrholdt; William J McKenna; Jens Mogensen; Petros Nihoyannopoulos; Stefano Nistri; Petronella G Pieper; Burkert Pieske; Claudio Rapezzi; Frans H Rutten; Christoph Tillmanns; Hugh Watkins
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

8.  Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI).

Authors:  Daniel R Messroghli; James C Moon; Vanessa M Ferreira; Lars Grosse-Wortmann; Taigang He; Peter Kellman; Julia Mascherbauer; Reza Nezafat; Michael Salerno; Erik B Schelbert; Andrew J Taylor; Richard Thompson; Martin Ugander; Ruud B van Heeswijk; Matthias G Friedrich
Journal:  J Cardiovasc Magn Reson       Date:  2017-10-09       Impact factor: 5.364

Review 9.  Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK).

Authors:  A Yilmaz; J Bauersachs; F Bengel; R Büchel; I Kindermann; K Klingel; F Knebel; B Meder; C Morbach; E Nagel; E Schulze-Bahr; F Aus dem Siepen; N Frey
Journal:  Clin Res Cardiol       Date:  2021-01-18       Impact factor: 5.460

10.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.

Authors:  Julian D Gillmore; Mathew S Maurer; Rodney H Falk; Giampaolo Merlini; Thibaud Damy; Angela Dispenzieri; Ashutosh D Wechalekar; John L Berk; Candida C Quarta; Martha Grogan; Helen J Lachmann; Sabahat Bokhari; Adam Castano; Sharmila Dorbala; Geoff B Johnson; Andor W J M Glaudemans; Tamer Rezk; Marianna Fontana; Giovanni Palladini; Paolo Milani; Pierluigi L Guidalotti; Katarina Flatman; Thirusha Lane; Frederick W Vonberg; Carol J Whelan; James C Moon; Frederick L Ruberg; Edward J Miller; David F Hutt; Bouke P Hazenberg; Claudio Rapezzi; Philip N Hawkins
Journal:  Circulation       Date:  2016-04-22       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.